Eton Pharmaceuticals, Inc. Quarterly Nonoperating Income (Expense) in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Eton Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2019 to Q3 2024.
  • Eton Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was -$8K, a 74.2% increase year-over-year.
  • Eton Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was -$87K, a 124% decline year-over-year.
  • Eton Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was $503K.
  • Eton Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was -$761K, a 24.4% increase from 2021.
  • Eton Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2021 was -$1.01M, a 17.1% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$87K -$8K +$23K +74.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$110K -$52K -$728K -108% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $618K -$11K +$115K +91.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $503K -$16K +$134K +89.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $369K -$31K +$119K +79.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $250K $676K +$894K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$644K -$126K +$117K +48.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$761K -$150K +$125K +45.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$886K -$150K +$97K +39.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$983K -$218K +$19K +8.02% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$1M -$243K +$4K +1.62% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$1.01M -$275K +$328K +54.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 -$1.33M -$247K -$15K -6.47% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$1.32M -$237K -$45K -23.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$1.27M -$247K -$415K -247% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$859K -$603K -$563K -1408% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-16
Q3 2020 -$296K -$232K -$309K -401% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-16
Q2 2020 $13K -$192K -$292K -292% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $305K $168K +$24K +16.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $281K -$40K Oct 1, 2019 Dec 31, 2019 10-K 2022-03-16
Q3 2019 $77K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $100K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 $144K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.